



NewLink Genetics Corporation
Investor Relations Department
2503 South Loop Drive
Ames, IA 50010
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

Company Profile

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

Press Releases [\[View all \]](#)

Nov 20, 2017
[NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children](#)

Nov 14, 2017
[NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer](#)

Nov 13, 2017
[NewLink Genetics to Participate in November Investor Conferences](#)

Nov 2, 2017
[NewLink Genetics Reports Third Quarter 2017 Financial Results and Updates Indoximod Program](#)

Oct 30, 2017
[NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 6, 2017
[Annual Report \(10-K\)](#)

Mar 31, 2017
[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017
[Quarterly Report \(10-Q\)](#)

Aug 3, 2017
[Quarterly Report \(10-Q\)](#)

May 5, 2017
[Quarterly Report \(10-Q\)](#)